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Background. Dementia is a common, debilitating feature of late Parkinson’s disease 
(PD). PD dementia (PDD) is associated with α-synuclein propagation, but coexistent 
Alzheimer’s disease (AD) pathology may coexist. Other pathologies (cerebrovascular, 
TDP-43) may also influence cognition. We aimed to describe the neuropathology 
underlying dementia in PD. 
 
Methods. Systematic review of autopsy studies published in English involving PD 
cases with dementia. Comparison groups included PD without dementia, AD, 
dementia with Lewy bodies (DLB), and healthy controls. 
 
Results. 44 reports involving 2002 cases, 57.2% with dementia, met inclusion 
criteria. While limbic and neocortical α-synuclein pathology had the strongest 
association with dementia, between a fifth and a third of all PD cases in the largest 
studies had comorbid AD. In PD cases with dementia, tau pathology was moderate or 
severe in around a third, and amyloid-β pathology was moderate or severe in over 
half. Amyloid-β was associated with a more rapid cognitive decline and earlier 
mortality, and in the striatum, distinguished PDD from dementia with Lewy bodies 
(DLB). Positive correlations between multiple measures of α-synuclein, tau, and 
amyloid-β were found. Cerebrovascular and TDP-43 pathologies did not generally 
contribute to dementia in PD. TDP-43 and amyloid angiopathy correlated with 
coexistent Alzheimer pathology. 
 
Conclusions. While significant α-synuclein pathology is the main substrate of 
dementia in PD, coexistent pathologies are common. In particular, tau and amyloid-β 
pathologies independently contribute to the development and pattern of cognitive 
decline in PD. Their presence should be assessed in future clinical trials where 
dementia is a key outcome measure.  
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INTRODUCTION 
 
Cognitive impairment, including dementia, is a common and debilitating feature in 
patients with Parkinson’s disease (PD). PD dementia (PDD) is distinguished from 
dementia with Lewy bodies (DLB) by the relative timing of the onset of cognitive 
symptoms versus motor signs. In PDD, the onset of dementia is usually several years 
after PD diagnosis; in DLB, cognitive symptoms occur within one year of the 
diagnosis of parkinsonism, or precedes it[1, 2]. However, patients with PD may have 
other causes of cognitive impairment and dementia, such as comorbid Alzheimer’s 
disease (AD) or cerebrovascular disease. These pathologies may be difficult to 
identify in vivo, as the clinical features often overlap with those of PDD, and there are 
no definitive biomarkers. The differentiation of dementia type is an important 
consideration in clinical research, as treatments under development are specifically 
targeted against abnormal accumulation of α-synuclein, which is the pathological 
hallmark of PDD and DLB[3], or tau or amyloid-β, which underlie AD[4, 5]. A better 
understanding of the contribution of different pathological substrates to the 
development of dementia in PD would be useful for the planning and analysis of the 
efficacy of these new treatments. 
 
Autopsy studies are the definitive approach to identify the pathological basis of 
dementia in PD. They also ensure that the clinical diagnosis of PD is accurate, which 
is important given known diagnostic error rates in vivo[6, 7]. We conducted a 
systematic review of autopsy studies in PD cases with dementia, in order to define the 
relative role of α-synuclein, tau, amyloid-β, and other pathologies, including 
transactive response DNA-binding protein 43 (TDP-43) and cerebrovascular disease, 
in the aetiology of cognitive decline in PD. 
 
PD is pathologically defined by two key features. Degeneration of the nigrostriatal 
dopaminergic system underlies the progressive motor syndrome that clinically defines 
the disease[8]. Accumulation of misfolded, insoluble aggregates of α-synuclein 
protein in the neuronal perikarya (Lewy bodies) and processes (Lewy neurites) is the 
second hallmark. According to the Braak staging model for PD (Braak-PD staging), 
α-synuclein pathology spreads in a stereotypical, caudal-to-rostral pattern in PD, from 
the brainstem through the limbic system to the neocortex. Propagation of α-synuclein 
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aggregates to the neocortical regions is the main substrate of cognitive decline in PDD 
and DLB[1, 2]. 
 
PDD is neuropathologically distinct from Alzheimer’s disease (AD)[9], the most 
common cause of dementia. Like PD, AD is defined at autopsy by two hallmark 
lesions. Neurofibrillary tangles are insoluble, intraneuronal bundles of 
hyperphosphorylated tau protein. Amyloid-β plaques are extraneuronal structures 
composed primarily of amyloid-β peptide. “Neuritic plaques” are amyloid-β 
aggregates with dystrophic tau-positive neurites that are characteristic of AD. 
 
Braak staging for tau pathology[10] defines the spread of tau-positive tangles and 
neuropil threads from the transentorhinal cortex (stages I-II), into the entorhinal 
cortex and hippocampus (stages III-IV), and finally to neocortical areas. Amyloid-β 
pathology is described in five Thal phases[11], from the neocortex to the entorhinal 
cortex and subcortical nuclei, and finally to the brainstem and cerebellum. The 
CERAD protocol[12] is widely used to grade the severity of neuritic plaques. 
 
In addition to Lewy and Alzheimer type abnormalities, various other pathologies can 
underlie dementia. TDP-43 aggregates contribute to cognitive decline in most forms 
of frontotemporal dementia[13], and cerebrovascular disease (infarcts, haemorrhages, 
and white matter lesions) contributes to vascular dementia. The specific pathology 
underlying vascular dementia varies, but primary causes are cerebral amyloid 
angiopathy (CAA), atherosclerosis, and cerebral small vessel disease[14].  
 
This novel systematic review included autopsy studies of pathologically-verified PD 
cases with a history of dementia. The primary objective was to define the extent of 
Lewy, Alzheimer, and other pathologies (cerebrovascular, TDP-43) in cases of PD 
with dementia. 
 
METHODS 
 
This review was conducted in accordance with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA)[15]. The protocol was predefined 
and registered with the Centre for Reviews and Dissemination’s International 
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Prospective Register of Systematic Reviews (PROSPERO) at 
www.crd.york.ac.uk/prospero/ on 13/02/2018 (registration CRD42018088691). 
 
Autopsy studies of pathologically verified PD, including cases with dementia 
diagnosed prospectively or retrospectively, were identified. The minimum sample size 
was five (including cases and controls). Only full text papers in English presenting 
original data were included. 
 
Comparators or controls were not mandatory for inclusion, but many studies 
compared PD cases with dementia to other groups, including PD cases without 
dementia, DLB, and AD. 
 
The primary outcome was the presence of dementia during life, defined by clinical 
diagnosis or by at least one objective test of cognitive function. Studies limited to PD 
with mild cognitive impairment were not included. 
 
Search criteria were piloted in five key articles, and then applied from 1946 (Medline, 
Ovid) or 1974 (Embase, Ovid) to January 2018. Medical subject headings (MeSH: 
Parkinson/disease/pa, Dement*.mp, Cogniti*.mp) were combined, and filtered to 
humans. Duplicates were removed. Search terms and syntax were adapted for 
LILACS (BIREME), CINAHL (EBSCO), and the Cochrane Library (Wiley), all up to 
January 2018. Reference lists within included articles and relevant reviews were 
handsearched, and the “cited by” function was applied to all records ultimately 
included in the review. The search terms were initially piloted for sensitivity by 
confirming that they identified five preselected key articles. The search strategies for 
each database are provided in the supplementary material. 
 
Preliminary screening relied on title and/or abstract screening, then relevant articles 
were read in full. Both stages of the selection process were independently conducted 
by two authors (CRS and NMM), with a third (KAG) resolving discrepancies. 
 
Data describing the type, location, and extent of pathological findings (including 
staining methods and criteria) were extracted, and statistical comparison methods 
were noted. Studies were individually assessed by one author for risk of selection, 
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detection, and reporting bias, using a modified version of the semiquantitative 
Cochrane tool[16]. The initial plan to use a modified Newcastle-Ottawa scale for this 
purpose was abandoned due to concerns about the scale’s validity[17]. Eligible 
studies were included in the review regardless of risk of bias. 
 
Some reports used the same cases; in determining the sample size of all studies 
combined, these cases were only counted once. Partial overlap between studies was 
not subjected to any adjustment because of the small numbers involved. In generating 
the bar charts to describe the severity of Alzheimer pathology, it was sometimes 
necessary to impute data where categories in the original report (e.g. absent and mild) 
had been collapsed. Values for imputation were based on average values when all 
studies were combined. Aggregation was done for each bar chart based on raw data. 
 
RESULTS 
 
Study selection and characteristics 
 
Electronic searching retrieved 1552 records, and 14 more were identified from hand 
searching. Excluding duplicates and non-human studies, 1519 records underwent 
preliminary screening; 84 were potentially relevant and were read in full. Forty of 
these were discarded, in most cases due to the lack of relevant detail or PD cases with 
dementia. Ultimately, 44 articles involving 41 study groups were included (Figure 1). 
Interrater agreement was 96.8% at initial screening, and 93.6% at the full text stage. 
 
The 44 reports involved 2002 cases with clinically diagnosed and pathologically 
verified PD, 1145 (57.2%) of whom had dementia. Dementia was primarily a clinical 
diagnosis, generally referencing the Diagnostic and Statistical Manual of Mental 
Disorders (DSM), but standard cognitive tests were often applied. Comparison groups 
included PD without dementia, DLB, AD, and healthy controls (Table 1).  
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Table 1. Characteristics of reports included in the systematic review. 
Author (year) [reference number] PD total 
n (%) PD with 
dementia Definition of dementia Comparison groups 
Aarsland et al. (2005)[18] 22 18 (81.2%) DSM-III-R None 
Apaydin et al. (2002)[19] 22 13 (59.1%) DSM-III-R None 
Ballard et al. (2006)[20] 28 28 (100%) DSM-III-R DLB 
Bancher et al. (1993)[21]a, b 28 12 (42.9%) MMSE <17 None 
Braak and Braak (1990)[22] 11 10 (90.9%) Clinical Controls, AD, trisomy 21 
Braak et al. (2005)[23] 88 79 (89.8%) MMSE <21 None 
Churchyard and Lees (1997)[24] 27 17 (63.0%) DSM-III Controls 
Colosimo et al. (2003)[25] 38 21 (55.3%) DSM-III-R None 
Compta et al. (2011)[26]c 56 29 (51.8%) DSM-IV None 
de la Monte et al. (1989)[27] 10 4 (40.0%) Clinical Controls and AD 
de Vos et al. (1995)[28] 18 12 (66.7%) DSM-III-R / MMSE <20 Controls 
Fujishiro et al. (2010)[29] 13 13 (100%) Clinical DLB 
Gaspar & Gray (1984)[30] 32 18 (56.3%) Clinical Controls 
Halliday et al. (2011)[31] 19 12 (63.2%) Clinical Controls and DLB 
Harding and Halliday (2001)[32] 41 16 (39.0%) CDR >0.5 DLB 
Horvath et al. (2013)[33] 155 109 (70.3%) Clinical None 
Howlett et al. (2015)[34]d 34 34 (100%) Clinical DLB 
Hughes et al. (1993)[35] 100 31 (31.0%) DSM-III / MMSE <20 None 
Hurtig et al. (2000)[36] 42 22 (52.4%) DSM-IV None 
Irwin et al. (2012)[37] 140 92 (65.7%) DSM-IV None 
Jellinger et al. (1991)[38]a, b 26 9 (34.6%) MMSE <17 Controls 
Jellinger et al. (2002)[39] 200 66 (33.3%) MMSE <20 None 
Jellinger and Attems (2006)[40] 17 17 (100%) Clinical DLB 
Jellinger and Attems (2008)[41] 68 32 (47.1%) MMSE <20 DLB 
Jendroska et al. (1996)[42] 50 23 (46.0%) DSM-III-R Controls 
Kalaitzakis et al. (2009)[43] 32 12 (37.5%) DSM-IV / ICD-10 DLB 
Kalaitzakis et al. (2011)[44] 93 41 (44.1%) DSM-IV / ICD-10 Controls, DLB, MSA, PSP 
Kempster et al. (2010)[45]c 129 69 (53.5%) DSM-IV None 
Kotzbauer et al. (2012)[46]  32 32 (100%) Clinical None 
Kövari et al. (2003)[47] 22 10 (45.5%) CDR >0.5 None 
Libow et al. (2009)[48] 18 18 (100%) DSM-IV None 
Mattila et al. (1998)[49]e 44 35 (79.5%) GDS >1 None 
Mattila et al. (1999)[50]e 45 35 (77.8%) GDS >1 None 
Mattila et al. (2000)[51]e 45 35 (77.8%) GDS >1 None 
Nakashima-Yasuda et al. (2007)[52] 90 21 (23.3%) Clinical Controls and DLB 
Perry et al. (1985)[53] 11 7 (63.6%) Clinical Controls and AD 
Ruffmann et al. (2016)[54] 104 55 (52.9%) DSM-IV / MDS DLB 
Sabbagh et al. (2009)[55] 51 51 (100%) DSM-IV None 
Sierra et al. (2016)[56] 20 10 (50%) MDS Controls, AD, DLB 
Tsuboi et al. (2007)[57] 7 7 (100%) Clinical DLB 
Vermersch et al. (1993)[58] 24 16 (66.6%) Clinical Controls and AD 
Walker et al. (2015)[59]d 3 3 (100%) MDS AD and DLB 
Whitehouse et al. (1983)[60] 9 5 (55.6%) Clinical Controls and PEP 
Wills et al. (2010)[61]f 35 
18 
18 (51.4%) 
7 (38.9%) 
Clinical Controls 
a These reports were based on the same cases. 
b There was potential overlap between these cases. 
c There was potential overlap between these cases. 
d There was potential overlap between these cases. 
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e These reports were based on the same cases. 
f This study obtained striata from 35 cases and inferior frontal gyri from 18. 
AD = Alzheimer’s disease, CDR = Clinical dementia rating, DLB = Dementia with Lewy bodies, DSM = Diagnostic and 
Statistical Manual of Mental Disorders, GDS = Global Deterioration Scale, ICD = International Classification of Diseases, 
MDS = Movement Disorder Society, MMSE = Mini-Mental State Examination, MSA = Multiple system atrophy, PD = 
Parkinson’s disease, PEP = Postencephalitic parkinsonism, PSP = Progressive supranuclear palsy. 
 
 
Seven studies excluded cases with coexistent tau pathology[24, 25, 31, 32, 44, 47, 
61], and one study required cases to have both Lewy and Alzheimer pathologies[59]. 
Differential diagnosis of PDD versus DLB typically relied on the one-year latency 
rule[1, 2]. However, some studies excluded cases with cognitive decline within 2 to 5 
years of motor onset[19, 32, 36, 37, 47, 57]. 
 
Risk of bias 
 
Overall, 77.3% of reports had a low risk of bias. Nine had an unclear risk, and one 
had a high risk of bias. Selection bias was unclear in 13 reports (29.5%) that did not 
report the source of autopsy cases. Two studies had a high risk of detection bias. The 
cases in one study were primarily hospital residents[48], and in the other, tissue 
samples were collected from NIA-funded AD centres[52]; either procedure may have 
led to datasets that do not representat typical PD populations. Detection bias was 
unclear in 24 (54.5%) reports due to omission of information about the pathological 
assessment procedures, including what stains were used, whether or not the 
neuropathologists were blind to clinical data, and what guidelines or diagnostic 
criteria had been consulted. Reporting bias was high in one study[48] that focused 
almost entirely on a single case in the results section, and omitted relevant medical 
and neuropsychological information for other cases. All other studies had a low risk 
of reporting bias (Supplementary Table 1). 
 
α-synuclein pathology 
 
Lewy pathology was detected by routine staining or antibodies to ubiquitin in earlier 
studies, while antibodies to α-synuclein were widely used following their introduction 
in 1998[62]. Two early studies found leading causes of dementia in PD to be 
comorbid AD, cortical Lewy body deposition, and cerebrovascular disease, though no 
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cause was found in a significant percentage[35, 42], probably due to older staining 
methods. 
 
Dementia was linked to Braak-PD or McKeith stage in several studies in a total of 
480 cases. In PD cases with dementia, α-synuclein pathology almost invariably 
extended to the limbic system or neocortex (85.3-100% of cases); neocortical 
involvement was more frequent than in PD without dementia in all four studies that 
conducted a comparison[26, 33, 37, 45]. Insoluble cortical α-synuclein levels were 
particularly overexpressed, though soluble levels were also raised, according to an 
analysis of the inferior frontal gyrus[61]. Limbic and neocortical Lewy body counts 
were approximately ten times higher in dementia cases[19]. A moderate total cortical 
Lewy body score had excellent sensitivity (90.9%) and specificity (90.0%) for 
detecting dementia in PD[36]. The severity of cognitive impairment correlated 
strongly with Braak-PD stage[23], and with Lewy body densities in the frontal, 
straight, angular, cingulate, and middle temporal gyri, particularly when cases with 
coexistent Alzheimer pathology were excluded[49, 51]. 
 
PD cases with dementia also showed higher Lewy pathology in subcortical regions 
relative to cognitively healthy PD cases. In the striatum, insoluble α-synuclein levels 
were twice as high[61]. In the amygdala and hippocampus, studies relying on 
ubiquitin stains found no association of Lewy bodies to dementia[24, 28, 50], but 
studies using α-synuclein stains found higher Lewy body densities in these regions 
that correlated with dementia severity[19, 31, 51]. Parahippocampal α-synuclein 
scores had excellent sensitivity (91-93%) and specificity (84-88%) for separating PD 
cases with and without dementia[32]. However, in the nucleus basalis, substantia 
nigra, and midbrain, no differences in α-synuclein burden were seen between PD 
without dementia, PDD, and DLB[19, 56].  
 
DLB groups tended towards greater global α-synuclein pathology than PDD, but 
differences were usually not significant[29, 31, 54]. Striatal α-synuclein differentiated 
PDD (29.4% of 17 cases) from DLB (76.5% of 17 cases, p<0.001) in one study[40]. 
Additionally, in the claustrum, α-synuclein deposition rose progressively from PD 
without dementia to PDD to DLB[43]. 
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The strong association between extensive α-synuclein pathology and dementia was 
challenged by some observations. Some large studies found that 15.2-44.7% of 181 
cognitively healthy PD cases had severe, neocortical-type pathology[26, 33, 37, 45]. 
One study described 17 PD cases with no dementia despite limbic and/or neocortical 
pathology, and concluded that no clear threshold of Lewy body burden can 
distinguish PD cases with and without dementia[25]. 
 
The opposite phenomenon, dementia cases with modest α-synuclein pathology, was 
also reported. In one study, 3 PD cases with dementia had no Lewy bodies outside the 
brainstem, and only mild or absent Alzheimer or vascular pathology[48]. Dementia 
cases with α-synuclein pathology confined to the brainstem were sporadically 
reported elsewhere: such cases accounted for 14.7% of one study of 109 dementia 
cases[33], but most studies reported much lower figures[18, 23, 25, 26, 32, 37, 46, 54, 
56, 59]. 
 
Alzheimer pathology 
 
Coexistent tau and amyloid-β pathology of varying severity was common in PD 
cases. Tau pathology was universally scored with Braak-tau staging. A third of cases 
with dementia had moderate or severe tau pathology (stages III-VI). There was 
heterogeneity in the methods used to quantify amyloid-β lesions. Most studies used 
CERAD criteria, and therefore considered neuritic plaque burden only. Moderate to 
severe amyloid-β pathology affected just over half of PD cases with dementia (Figure 
2). 
 
The proportion of PD with comorbid AD varied markedly. The four largest studies 
(n=88 to n=200) that defined AD as intermediate or high probability by NIA-Reagan 
criteria (accounting for both plaques and tangles) were reasonably consistent: 
comorbid AD was diagnosed in 19.3%[23], 20.0%[33], 28.6%[37], and 31.5%[39] of 
PD cases. Three of these four studies reported the rate of comorbid AD by these 
criteria in PD cases with dementia, where there was more variation: 21.5%[23], 
38.2%[37], and 89.4%[39] (Figure 2). 
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Some early studies linked dementia in PD to marked depletion of cholinergic neurons 
in the basal forebrain and cortex[30, 53, 60], as also typifies AD. Comorbid AD was 
associated with greater cortical and amygdala atrophy in PD cases with dementia, but 
the striatum was severely atrophic regardless of comorbid AD[27]. 
 
Tau and amyloid-β pathologies in PD cases with dementia were typically graded as 
moderate to severe only in the entorhinal cortex, and mild in the hippocampus, 
according to two descriptive studies. The neocortex was generally unaffected by tau 
and variably affected by amyloid-β[22, 28]. The prefrontal cortex was more affected 
by tau pathology than the temporal cortex in PDD cases (a rare pattern in AD); the 
occipital and cingulate cortices were rarely affected[58]. 
 
Two reports based on the same study cohort described advanced Alzheimer pathology 
in PD cases with severe dementia, and concluded that dementia in PD was due to 
comorbid AD[21, 38]. Later studies from the same research group supported this[39, 
41]. Alzheimer pathology was substantially higher in these studies than in other series 
(Figure 2). 
 
Striatal amyloid-β measures differentiated PDD from DLB. All of 17 DLB cases had 
moderate to severe striatal amyloid-β in one study, compared to only 17.6% of 17 
PDD (p<0.001)[40]. A study excluding cases with significant neurofibrillary 
pathology similarly found higher striatal amyloid-β in DLB, which correlated with 
dementia severity, and had 100% sensitivity and 66.7% specificity for differentiating 
the 10 DLB cases from 12 PDD cases[31]. In another study, 92.9% of 14 DLB cases 
had dense-core plaques in the striatum, which were entirely absent in 41 PDD cases. 
The higher frequency of severe striatal amyloid-β in DLB was not significant in this 
analysis[44]. 
 
Midbrain and cerebellar amyloid-β was higher in DLB than PDD in one study of 30 
combined cases[29], but not in another of 20 cases, possibly because that study 
involved PDD cases that were approximately seven years younger on average[56]. In 
both studies, subtentorial tau was comparable in PD (regardless of dementia) and 
DLB. Claustrum amyloid-β was comparable between PDD and DLB, but exceeded 
levels in cognitively healthy PD, while tau was negligible in all three groups[43]. 
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Finally, in cases with comorbid Lewy and Alzheimer pathologies, greater global 
amyloid-β (significant in the temporal and cingulate cortices) and tau (significant in 
the frontal and cingulate cortices) was found in those diagnosed clinically with DLB, 
relative to PDD[59]. 
 
TDP-43, argyrophilic grain, and cerebrovascular pathologies 
 
Only one study examined TDP-43 pathology in PD cases with comparators [52]. 
Hippocampal and entorhinal slides were positive in 7.2% of 69 PD without dementia, 
19.0% of 21 PDD, 31.3% of 80 DLB plus AD, none of the 10 DLB cases without AD, 
and 3% of 33 healthy controls. Significant differences were found only when 
comparing a disease group to healthy controls, and a dementia group with a non-
dementia group. 
 
Two studies reported argyrophilic grain disease in approximately 5% of PD cases 
(n=88 and n=140), with no association with dementia[23, 37]. 
 
Cerebrovascular pathology was found in 16.7-28.6% of cognitively healthy PD cases, 
and 15.6-44.4% of those with dementia[18, 33, 37, 54], though the definition of 
vascular pathology varied between studies. Individually, none of these studies found a 
significant association between cerebrovascular disease and dementia. Combining the 
results of the individual studies did not produce a significant result (total n=421, 
χ2=0.01, p=0.92). 
 
Unlike other types of cerebrovascular pathology, CAA was significantly more 
common in dementia[26, 37]. Capillary CAA was most often severe in PD cases with 
dementia (>50%); generalised CAA affecting meningeal and cortical vessels was 
severe in around a quarter, and moderate in around a third. In contrast, over three-
quarters of cognitively healthy PD cases were completely unaffected[41]. 
 
Relative contribution of α-synuclein, amyloid-β, and tau to dementia 
 
Multiple indices of abnormal α-synuclein, amyloid-β, and (less consistently) tau were 
significant predictors of dementia in PD based on univariable regressions[33, 37, 54]. 
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One study of 22 PD cases found that most of the variance in cognitive scores was 
accounted for by Lewy pathology in the entorhinal, anterior cingulate, and temporal 
cortices, with smaller contributions from entorhinal and temporal amyloid-β[47]. The 
contribution of amyloid-β and tau was typically lower by multivariable regression 
(Table 2). Braak-tau stage remained independently associated in one study[33] but 
Lewy pathology was consistently the best predictor. The predictive values of 
amyloid-β and tau was lost in another model when cortical Lewy bodies were added; 
strong collinearity of these pathologies precluded further multivariable analysis[26]. 
 
One study of 104 cases used receiver operating characteristic (ROC) curves to predict 
dementia in PD, and found that mean cortical Lewy body score alone was the best 
predictor (area under the curve [AUC] 0.80, 95% confidence interval [CI] 0.72-
0.88)[54]. However, another study of 56 cases indicated that diagnostic accuracy was 
improved by the addition of indicators of amyloid-β and tau pathology (AUC 0.95, 
95% CI 0.88-1.00)[26]. 
 
A multivariable regression examining dementia severity found that anterior cingulate 
and entorhinal Lewy body densities together accounted for approximately 60% of the 
variance in cognitive scores; values for amyloid-β and tau were not significant[47]. 
Linear regression in another study again found the best fit for cingulate Lewy 
pathology as a predictor of dementia severity; additionally, temporal neurofibrillary 
tangle load was a marginally significant predictor. When cases with severe amyloid-β 
load were excluded, frontal α-synuclein was the sole significant predictor[51]. 
 
Only one study (n=22) found that cognitive scores were unrelated to any measure of 
α-synuclein, amyloid-β, or tau pathology, though the Lewy body score predicted the 
annual rate of cognitive decline[18]. The best predictor of annual decline was a 
summated score incorporating both Lewy and Alzheimer pathologies of the prefrontal 
cortex, according to a study that used multiple backward regressions[34]. 
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Table 2. Significant predictors of dementia in PD by multivariable regression. 
Author (year) [reference 
number]; method Variable 
Odds 
ratio 
95% confidence 
interval p-value 
Horvath et al. (2013)[33] Lewy body score > 6a 4.20 1.67-10.59 0.002 
Multivariable logistic Braak-tau stage 1.60 1.13-2.27 0.009 
regression     
Irwin et al. (2012)[37] Total cortical Lewy score 4.06 1.87-8.81 < 0.001 
Stepwise-selection model APOE ε4 genotype 4.19 1.28-13.75 0.018 
building procedure     
Ruffmann et al. (2016)[54] Mean cortical Lewy score 4.23 2.19-8.98 < 0.001 
Multivariable logistic     regression 
    a By 1996 McKeith criteria[63]. 
 
 
None of the studies that assessed the value of cerebrovascular disease pathology 
(including CAA) for predicting dementia found a significant association, using 
univariable or multivariable regression methods[26, 33, 37, 54]. 
 
The motor-cognitive interval and mortality 
 
The latency from motor to cognitive onset in PD was studied in four survival 
analyses[20, 46, 54, 55] with a combined total of 166 PD cases of dementia; three of 
these studies[20, 54, 55] associated higher amyloid-β with a shorter motor-cognitive 
interval. Moderate to severe plaque pathology reduced the motor-cognitive interval by 
4.7 years on average[55]. Additionally, a multivariable regression model established 
cortical amyloid-β as the only significant predictor of a shorter motor-cognitive 
interval[54]. No associations of α-synuclein or tau pathologies with the motor-
cognitive interval were found in any of these studies. 
 
In another study (n=28), a longer time to dementia correlated moderately with lower 
plaque scores, and more weakly with less severe α-synuclein pathology, but not with 
Braak-tau stage. A significant correlation (r = –0.37, p=0.04) was also observed with 
the amount of choline acetyltransferase in the temporal cortex, indicating that 
cholinergic activity in this area is reduced in cases with a longer duration of PD 
preceding cognitive onset[20]. 
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Other studies explored the association of pathology with mortality. One study (n=32) 
linked increased amyloid-β pathology to higher mortality using Kaplan-Meier curves 
[46]. A larger study (n=200) additionally found a weaker association of tau pathology 
to mortality. Coexistent Alzheimer lesions decreased life expectancy by a mean of 4.5 
years. Multivariable regression found that dementia, tau pathology, and particularly, 
neuritic plaque pathology all predicted lower survival[39]. 
 
Interaction between neuropathological disease processes 
 
Moderate correlations were reported between Braak-tau stage and cortical and striatal 
amyloid-β load[26, 31] and Thal phase[33]. Alzheimer lesions also correlated 
positively with α-synuclein burden. Braak-tau stage correlated weakly with Braak-PD 
stage, global Lewy body score, and global, cortical, and striatal Lewy neurite 
scores[26, 31, 33]. Stronger correlations were generally found between α-synuclein 
and amyloid-β. Global Lewy body scores correlated better with Thal phase than 
Braak-tau stage, though the coefficient was still modest[33]. Moderate correlations 
were found between multiple indices of α-synuclein pathology (Braak-PD stage, 
cortical Lewy body score, and striatal and hippocampal Lewy neurites) and cortical 
and striatal amyloid-β pathology[26, 31]. Another study demonstrated moderate 
correlations between striatal α-synuclein and cortical and hippocampal plaques, but 
not with hippocampal tangles[57]. 
 
CAA correlated moderately with tau pathology, and more modestly with cortical 
amyloid-β load[26]. Similarly, TDP-43 pathology correlated strongly with Braak-tau 
stage[52]; unfortunately, the potential association with amyloid-β was not analysed. 
 
DISCUSSION 
 
The results of the systematic review indicate that limbic and neocortical α-synuclein 
pathology is present in virtually all cases of PD with dementia. Coexistent pathologies 
that contribute to dementia, most notably Alzheimer-related changes, are common. Of 
the studies that defined pathological AD by NIA-Reagan criteria, between a fifth and 
a third of all PD cases fulfilled that diagnosis[23, 33, 37, 39]. In the PD cases with 
dementia, tau pathology was moderate or severe in around a third, and amyloid-β 
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pathology was moderate or severe in just over half. Even taking account of 
differences across studies, we can reliably conclude that tau and amyloid-β 
pathologies are both common in PD cases at autopsy, particularly those with 
dementia. 
 
The relative contribution of Alzheimer versus α-synuclein pathologies was more 
difficult to define, due to variation between studies. Reports from one research group, 
with some overlap in study samples, found advanced Alzheimer pathology in most 
PD cases with dementia[21, 38, 39, 41]. In other studies, Alzheimer pathology was 
universally less frequent and less severe. These differences were not explained by 
systemic differences in dementia severity, age, disease duration, or case selection 
procedures. While global tau indices independently predicted dementia in PD cases in 
one study[33], two other studies found no such association[37, 54]. One possible 
explanation for this was the lower α-synuclein burden in the first study compared to 
the other two, which might have allowed the independent contribution of tau to 
emerge. Another factor may be the distribution of tau pathology; neurofibrillary 
tangles in the temporal lobe were linearly associated with dementia severity in 
another study[51]. 
 
Combined, these results indicate that tau pathology contributes to dementia in a subset 
of PD cases, particularly when α-synuclein deposition is relatively low or tau 
deposition relatively high. Amyloid-β, in contrast, was not independently related to 
dementia in any study. Thus, tau has a closer relationship with cognitive status in PD 
than amyloid-β, which is consistent with observations in AD[64]. These findings have 
implications for clinical trials of disease-modifying immunotherapies in PD: using 
biomarkers to quantify coexistent tau pathology will be helpful, particularly for 
studies that include cognitive impairment as a key outcome. The value of 
immunotherapies targeting tau deposition in PD will need to be evaluated. 
 
While amyloid-β pathology was not associated with the presence of clinical dementia 
diagnosis in PD, moderate to severe deposition was strongly linked to a more rapid 
cognitive deterioration[20, 31, 54, 55], as well as earlier mortality[39, 46]. 
Longitudinal studies measuring amyloid-β in vivo (e.g. by cerebrospinal fluid assays 
or neuroimaging) support its association with the rate of cognitive decline in PD, 
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showing that higher amyloid-β predicts a greater decrease in cognitive scores[65, 66]. 
Identifying amyloid-β deposition is therefore likely to become relevant in disease-
modifying PD trials, either as part of selection criteria, or as a stratification factor for 
sub-group analyses. 
 
The consistent association of amyloid-β with the motor-cognitive interval in both 
autopsy and biomarker studies indicates that it is a key factor distinguishing DLB 
from PDD. The most striking differences were in the striatum. Moderate-severe 
striatal amyloid-β had good specificity (66.7-82.4%) for DLB against PDD[31, 40], 
and dense-core striatal plaques were present only in DLB[44]. Neuroimaging findings 
indicate that these differences are detectable in vivo, with DLB cases showing higher 
cortical, cingulate, and striatal amyloid-β than PDD cases[67]. It remains unclear how 
early these differences emerge; further studies of this would help to refine the 
diagnostic criteria for prodromal PD. These criteria rely on features such as rapid eye 
movement sleep behaviour disorder, hyposmia, and autonomic dysfunction[68], all of 
which also frequently precede DLB, such that the criteria often capture cases who 
progress to DLB rather than PD[69]. Amyloid-β biomarkers, which are already 
incorporated into criteria for prodromal and preclinical AD[70, 71], may also have a 
place in prediction of PD versus DLB. 
 
The relationship between α-synuclein deposition and dementia was strong, as 
expected, but there was again some variation between studies. Global cortical α-
synuclein was generally the best predictor of dementia[33, 37, 47, 51, 54], though 
cingulate or frontal scores had the best correlation in one study[51], and the addition 
of tau and amyloid-β scores improved predictive accuracy for dementia in 
another[26]. Neocortical, limbic, and paralimbic α-synuclein burden was almost 
universally more severe in dementia cases, and had excellent sensitivity and 
specificity for distinguishing these cases from PD without dementia[32, 36]. While 
these findings strongly support Braak theory[72] and the role of extensive α-synuclein 
deposition as the primary substrate of dementia in PD, some exceptions to this rule 
were observed. 
 
Firstly, significant α-synuclein deposition in limbic or neocortical areas was often 
found in PD cases who did not have a history of cognitive impairment. Such cases 
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accounted for around 15-45% of the cognitively healthy PD group in the largest 
studies[26, 33, 37, 45]. Other large autopsy studies similarly reported relatively severe 
α-synuclein, as well as tau and amyloid-β pathologies, in many elderly cases with 
neither motor nor cognitive impairment during life[73, 74]. Higher cognitive reserve 
may explain the variance between pathological and clinical severity in AD[75], and 
this could also apply to PD[76]. Unfortunately, too few studies reported proxy 
measures of cognitive reserve, such as educational or occupational attainment, to 
allow us to test this. Neural plasticity, genetics, and environmental exposures may 
also explain the variance in these observations; all of these are worthy of further study 
in the context of PD. 
 
Secondly, a rare but intriguing finding was the occurrence of dementia cases with 
relatively modest, brainstem-type α-synuclein pathology. The cognitive decline in 
these cases is presumably due to a pathology distinct from the primary condition. 
Comorbid AD probably accounts for the majority of these, but some individual cases 
may have had other problems, including vascular or frontotemporal dementia. 
Alternatively, cholinergic dysfunction originating in the basal forebrain, which was 
related to cognition in several studies[30, 53, 60], might be sufficient to independently 
cause dementia in a small number of cases. 
 
Several other pathologies may contribute to dementia in PD. CAA was significantly 
more common in dementia cases, and correlated with coexistent Alzheimer 
pathology[26, 37, 41]. Other cerebrovascular pathologies were not more common in 
dementia[18, 33, 37, 54], even when the studies were combined. TDP-43 did not 
contribute to dementia in the only study that assessed this; while it correlated strongly 
with tau pathology[52], the correlation with amyloid-β pathology was not assessed. 
Animal models indicate that amyloid-β induces TDP-43 misfolding and 
aggregation[77]; the potential for this in PD could be examined in future research. 
Argyrophilic grain disease was rare and not associated with dementia in PD[23, 37], 
and is likely an incidental or age-related finding. Thus, while these molecular 
pathologies are common in PD – particularly in dementia cases, and most of all in 
cases with comorbid AD – they do not generally contribute to cognitive decline. 
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Finally, previous in vitro and animal studies indicate that α-synuclein, amyloid-β, and 
tau may promote one another’s aggregation to accelerate neurodegeneration and 
dementia[78-82]. Multiple studies in the present review found correlations that 
support this theory in PD cases[19, 26, 31, 33, 51]. This suggests that disease-
modifying therapies targeted against one pathology may inhibit the proliferation of 
another, increasing the overall benefit. This effect has been observed in a murine 
model, in which mice overexpressing α-synuclein were protected from both cognitive 
and motor impairment after treatment with an antibody for tau[83]. How this would 
translate to clinical research involving humans remains to be evaluated. 
  
Limitations 
 
Methodological limitations in the studies assessed included small sample sizes in 
many, and an absence of power calculations. Dementia ascertainment was 
retrospective in 32 reports (72.7%), being derived from non-standardised medical 
notes. The retrospective distinction of PDD from DLB may be difficult[84], though 
some studies required a longer motor-cognitive interval in order to exclude 
ambiguous cases[19, 32, 36, 37, 47, 57]. Several studies assessed cognition 
objectively but used short screening instruments (e.g. the Mini-Mental State 
Examination) with limited sensitivity and specificity for dementia in PD[85]. Almost 
a third of studies did not report the source of the autopsy cases, and more than half 
omitted information about the neuropathological assessment procedures. 
Finally, differing protocols for the pathological assessment of amyloid-β sometimes 
made comparisons difficult. Newer studies are likely to use the most recent NIA 
criteria for pathological AD[86], which incorporate both Thal and CERAD scoring; 
this will help overcome this variation in future research. In the present review, only a 
limited number of studies applied NIA-Reagan criteria[18, 19, 29, 39], and there was 
major variation in the proportion of cases with comorbid AD between these studies. 
 
The review itself was potentially limited by aspects of the electronic search strategy. 
There was some potential for publication bias: 8 potentially relevant unpublished 
articles were found that could not be retrieved online. Moreover, the exclusion of 
articles in languages other than English (n = 6, titles provided in supplementary 
material) may have led to the omission of some relevant detail. 
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Conclusions 
 
Several disease processes (particularly Alzheimer-related) are common in PD, and are 
often severe enough to affect cognition, thereby adding to the effects of α-synuclein 
pathology. Tau pathology contributes to dementia in a subset of cases, and amyloid-β 
pathology confers a worse prognosis, characterised by an accelerated cognitive 
decline and earlier mortality. A synergistic interaction between α-synuclein, tau, and 
amyloid-β means that they promote one another’s aggregation, leading to a more 
aggressive disease course. Accordingly, both tau and amyloid-β should be assessed in 
clinical trials of new disease-modifying therapies targeting α-synuclein, particularly 
when cognition is included as a study outcome. This will improve the chance of 
showing efficacy, and reduce the risk of a negative finding driven by the presence of 
coexistent pathologies. 
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Figures 
 
 
 
Figure 1. PRISMA flow diagram showing selection of autopsy studies for inclusion in 
the systematic review. 
PRISMA, Preferred Reporting Items for Meta-Analyses and Systematic Reviews. 
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Figure 2. Severity of coexistent Alzheimer pathology in cases of Parkinson’s disease 
with dementia. 
 
(A) Severity of amyloid-β pathology using CERAD criteria, except for Horvath et al., who used Thal 
phases, and Braak et al., who used a semiquantitative scoring method. (B) Severity of tau pathology by 
Braak-tau staging. (C) Likelihood of Alzheimer’s disease by NIA-Reagan criteria. CERAD, 
Consortium to Establish a Registry for Alzheimer’s disease; NIA, National Institute on Aging. a Data 
were imputed for two or more categories. b There was potential overlap between these cases. 
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Supplementary table: Risk of bias assessments 
 
Author (year) Selection Detection Reporting Overall risk 
Aarsland et al, (2005)     
Apaydin et al. (2002)     
Ballard et al. (2006)     
Bancher et al. (1993)     
Braak & Braak (1990)     
Braak et al. (2005)     
Churchyard and Lees (1997)     
Colosimo et al. (2003)     
Compta et al. (2011)     
de la Monte et al. (1989)     
de Vos et al. (1995)     
Fujishiro et al. (2010)     
Gaspar and Gray (1984)     
Halliday et al. (2011)     
Harding and Halliday (2001)     
Horvath et al. (2013)     
Howlett et al. (2015)     
Hughes et al. (1993)     
Hurtig et al. (2000)     
Irwin et al. (2012)     
Jellinger and Attems (2006)     
Jellinger and Attems (2008)     
Jellinger et al. (1991)     
Jellinger et al. (2002)     
Jendroska et al. (1996)     
Kalaitzakis et al. (2009)     
Kalaitzakis et al. (2011)     
Kempster et al. (2010)     
Kotzbauer et al. (2012)     
Kövari et al. (2003)     
Libow et al. (2009)     
Mattila et al. (2000)     
Mattila et al. (1999)     
Mattila et al. (1998)     
Nakashima-Yasuda et al. (2007)     
Perry et al. (1985)     
Ruffmann et al. (2016)     
Sabbagh et al. (2009)     
Sierra et al. (2016)     
Tsuboi et al. (2007)     
Vermersch et al. (1993)     
Walker et al. (2015)     
Whitehouse et al. (1983)     
Wills et al. (2010)     
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Supplementary material: Systematic review search strategies 
 
The following search strategies were used to identify relevant articles for the 
systematic review. 
 
Medline / Embase 
 
1. Parkinson disease/pa [Pathology] 
2. Dement*.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, nm, kf, px, rx, an, ui, 
sy] 
3. Cogniti*.mp. [mp=ti, ab, hw, tn, ot, dm, mf, dv, kw, fx, nm, kf, px, rx, an, ui, 
sy] 
4. 2 or 3 
5. 1 and 4 
6. limit 5 to humans 
7. remove duplicates from 6 
 
CINAHL using advanced search 
 
S1: (MH “Parkinson Disease/PA) 
S2: “Dement*” 
S3: “Cogniti*” 
S4: SR OR S3 
S5: S1 AND S4 
Limiters – Human; Exclude MEDLINE records 
 
LILACS 
 
Parkinson* disease AND dement* OR cogniti* 
Filters – LILACS, Humans 
 
Cochrane Library using advanced search 
 
#1 MeSH descriptor: [Parkinson disease] explode all trees with qualifier(s): 
[Pathology – PA] 
#2 dement* 
#3 cogniti* 
#4 #2 or #3 
#5 #1 and #4 
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Supplementary material: Potentially relevant articles in other languages 
 
The following articles were excluded from the systematic review during preliminary 
screening because they were not fully available in English. 
  
Dubois, B., Hauw, J. J., Ruberg, M., Serdaru, M., Javoy-Agid, F., & Agid, Y. (1985).  
Dementia and Parkinson’s disease: biochemical and anatomo-clinical 
correlation. Revue Neurologique, 141(3), 184-193. [French]. 
 
Iwatsubo, T. (1999). Parkinson’s disease, dementia with Lewy bodies, multiple  
system atrophy and alpha-synuclein. Rinsho Shinkeigaku – Clinical 
Neurology, 39(12), 1285-1286. [Japanese]. 
 
Jansen, E. N., & de Vos, R. A. (1994). Dementia in Parkinson disease: Lewy body  
disease or Alzheimer’s disease? Nederlands Tijdschrift voor Geneeskunde, 
138(26), 1305-1309. [Dutch]. 
 
Kretzschmar, H. A., & Neumann, M. (2000). Neuropathological diagnosis of  
neurodegenerative and dementia diseases. Pathologe, 21(5), 364-374. 
[German]. 
 
Yoshimura, M. (1997). Diffuse Lewy body disease. Rinsho Shinkeigaku – Clinical  
Neurology, 37(12), 1134-1136. [Japanese]. 
 
Yoshimura, M., Mori, H., Tomonaga, M., Yamanouchi, H., & Kuzuhara, S. (1984).  
Loss of neurons in the nucleus basalis of Meynert in Parkinson disease with 
dementia, “diffuse Lewy body disease” and senile dementia of Alzheimer 
type. Nihon Ronen Igakkai Zasshi, 21(6), 580-587. [Japanese]. 
 
 
